Topic resource collection
Approved comparison material connected to this topic.
7 resourcesRead both sides
Selective androgen receptor modulators (SARMs) and growth hormone secretagogues are often conflated in research discussions, but their mechanisms are fundamentally different. SARMs bind androgen receptors directly. Mimicking test…
CJC-1295 with DAC GHRH receptor agonist with albumin binding 2mg weekly subcutaneous 8 days Indirect. Restores pulsatile GH → LH normalisation → testosterone synthesis Extended half-life allows weekly dosing; preserves natural GH…
MK 677 (Ibutamoren) Ghrelin receptor agonist. Stimulates continuous GH release 12.5–25mg daily Once daily (oral or subcutaneous) 15–25% increase in free testosterone over 8–12 weeks in clinical trials Best for sustained GH elevat…
The table below compares the three primary peptide approaches for growth hormone stimulation and downstream testosterone support. Categorized by mechanism, dosing complexity, and realistic timeline. GHRH Analogs (CJC-1295 with DA…
| Peptide | Target Receptor | Mechanism | Half-Life | Typical Dosing | Primary Use Case | Professional Assessment ||—|—|—|—|—|—|| Kisspeptin-10 | GPR54 (hypothalamus) | Stimulates pulsatile GnRH release | 28 minutes | 0.24 nmol/k…
| Compound | Primary Mechanism | HPG Axis Impact | Typical Research Dose | Time to Measurable Effect | Recovery After Cessation | Professional Assessment ||—|—|—|—|—|—|| Gonadorelin | GnRH receptor agonist. Stimulates LH/FSH rele…
| Peptide | Mechanism of Action | Typical Dosing Protocol | Intratesticular T Preservation | Fertility Preservation | Practical Limitations | Professional Assessment ||—|—|—|—|—|—|| HCG (Human Chorionic Gonadotropin) | LH recepto…